ロード中...
Cost-Effectiveness of Tafamidis Therapy for Transthyretin Amyloid Cardiomyopathy
BACKGROUND: In patients with transthyretin amyloid cardiomyopathy (ATTR-CM), tafamidis reduces all-cause mortality and cardiovascular hospitalizations, and slows decline in quality-of-life compared with placebo. In May 2019, tafamidis received expedited approval from the US FDA as a breakthrough dru...
保存先:
| 出版年: | Circulation |
|---|---|
| 主要な著者: | , , , , , , , , , , |
| フォーマット: | Artigo |
| 言語: | Inglês |
| 出版事項: |
2020
|
| 主題: | |
| オンライン･アクセス: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7156331/ https://ncbi.nlm.nih.gov/pubmed/32078382 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1161/CIRCULATIONAHA.119.045093 |
| タグ: |
タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!
|